The Neuro’s drug discovery initiative supports research by developing assays shared with the scientific community
In the past 40 years, the model of drug discovery used by the pharmaceutical industry, while proving successful for some applications, has produced very little for neurodegenerative diseases.
“We have to ask if there is a better way to find therapies that will modify the course of diseases, slowing or stopping them from progressing. While Open Science is not going to solve every problem, it will be a big part of the solution.”“Take Parkinson’s disease, for instance: there have been zero new disease modifying medications developed in the last 40 years, despite hundreds of millions of dollars being invested in research,” says Dr. Edward Fon, whose lab focuses on molecular and cellular research into Parkinson’s disease. “We have to ask if there is a better way to find therapies that will modify the course of diseases, slowing or stopping them from progressing. While Open Science is not going to solve every problem, it will be a big part of the solution.”
The Neuro’s drug discovery initiative aims to support research by developing assays that investigate different aspects of target cells and sharing these assays with colleagues around the world. The main vehicle for sharing assays is The Neuro’s Induced Pluripotent Stem Cell (iPSC) platform, developed recently with seed money generously donated by Sebastian van Berkom and Ghislaine Saucier.
“We can provide industry-standard assays researchers can use to test compounds,” says Thomas Durcan, another Parkinson’s researcher who manages the iPSC platform. “In collaboration with researchers at Université Laval, we reprogram blood cells from patients with neurological diseases into stem cells, and then transform the stem cells into the type of neural cells most impacted in neuropathology.”
This gives researchers the ability to compare normal and diseased states of the cells within one patient, which has long been possible for some diseases but is a novel advance for neurological research. The Centre for Drug Research and Development, a Canadian nonprofit organization that aims to speed the translation of discoveries into therapies, and the international Structural Genomics Consortium have both formed partnerships with the Tanenbaum Open Science Institute to use the iPSC platform.
“If we can identify potential compounds for targeting diseases such as Parkinson’s and share them so they can be screened and tested throughout the scientific community, we can accelerate the rate of discovery,” says Dr. Fon. “Other researchers can benefit from the resources we develop, and the chances of 100 laboratories finding something useful is much greater than that of one lab working alone. If we can come up with something leading to treatment for Parkinson’s disease, that would be an incredible payback.”
Learn more: Accelerating drug discovery with Open Science
The Latest on: Open Science
via Google News
The Latest on: Open Science
- The Future of Critical Zone Science: Call for Paperson May 3, 2021 at 7:03 am
Contributions are invited to a new cross-journal special collection that describe novel advances in critical zone research, with specific consideration for transferable and broadly applicable science.
- Christopher Austin reflects on translational science at the NIH’s 10-year-old NCATS, now that he’s heading for the exiton May 2, 2021 at 3:32 pm
Austin, founding director of the NIH’s National Center for Advancing Translational Sciences, is joining the venture capital firm Flagship Pioneering ...
- Royal Society Open Scienceon April 20, 2021 at 5:00 pm
Trix, the tyrannosaur ... A team of researchers from the SINAI Department of Computer Science, CEATIC and Universidad de Jaén has found that Twitter posts with negative sentiments are more likely ...
- THE OPEN SCIENCE GRID The Next Five Years: Distributed High Throughput Computing for the Nation's Scientists, Researchers, Educators, and Studentson April 19, 2021 at 5:00 pm
Grid computing developments occurred in parallel to the development of the LHC experiments. The Open Science Grid (OSG) is the major facilitator of Grid Computing in the U.S. Researchers subsequently ...
- A guide to Plan S: the open-access initiative shaking up science publishingon April 11, 2021 at 5:00 pm
As the first papers under these mandates are published, Plan S supporters say it’s the start of a journey towards open science. But most research funders haven’t signed up yet, and ...
- Open Hardware For Open Science – Interview With Charles Fracchiaon April 10, 2021 at 4:59 pm
Open Science has been a long-standing ideal for many researchers and practitioners around the world. It advocates the open sharing of scientific research, data, processes, and tools and ...
- Calls for Further Inquiries Into Coronavirus Originson April 7, 2021 at 7:13 am
As scientists, social scientists, and science communicators, including signatories of the March 4, 2021 open letter on COVID-19 origins, we believe there is a better way forward. In our previous ...
- Royal Society Open Scienceon March 30, 2021 at 5:00 pm
Royal Society Open Science is a new open journal publishing high-quality original research across the entire range of science on the basis of objective peer-review. The journal covers the entire ...
- Systematization of clinical knowledge for developmental disability support based on open science type researchon March 28, 2021 at 9:41 am
(1) The development of the evidence construction platform based on the open science type research method led by citizens is completed, and it will be used in various regions and areas.(2) Summarize ...
- Psychology Todayon March 15, 2021 at 8:05 am
I asked, a little timidly. “Very well,” the adventurer pointed at a bottle of potion labelled “Open Science Me” on a glass table behind me. I examined the bottle and sipped it carefully ...
via Bing News